Headquartered in Foster City, CA Fiscal year ends December NASDAQ: GERN geron.com
Geron Corporation is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for blood cancers (hematologic malignancies). Its sole commercial product, RYTELO (imetelstat), is a first-in-class oligonucleotide telomerase inhibitor approved in both the United States and the European Union for the treatment of adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. RYTELO works by inhibiting telomerase enzymatic activity to target abnormal bone marrow cells. The company is also advancing a pivotal Phase 3 clinical trial (IMpactMF) of imetelstat in JAK-inhibitor relapsed/refractory myelofibrosis and conducting studies in other hematologic malignancies. Geron estimates its current U.S. addressable market includes approximately 8,000 second-line LR-MDS patients. The company trades on Nasdaq under the ticker GERN. Updated
Monday's top analyst upgrades and downgrades included Amazon.com, Canopy Growth, CarMax, Chipotle Mexican Grill, Geron, Hess, Inogen, Occidental Petroleum, Snap, Teva Pharmaceutical, Vail Resorts and Zoom Video Communications.
The top analyst upgrades, downgrades and initiations for Tuesday included Annaly Capital Management, Amazon.com, Enterprise Products Partners, Kinder Morgan, Lululemon Athletica, RealReal, Snap, Square and Under Armour.
The top analyst upgrades, downgrades and initiations seen on Tuesday included Anadarko Petroleum, Apple, Charter Communications, Geron, KLA-Tencor, PVH, SAP, Walt Disney and United States Steel.
The top analyst upgrades, downgrades and initiations seen on Wednesday included Activision Blizzard, Biogen, Deere, DocuSign, Ford, Freeport-McMoRan, General Motors, Lattice Semiconductor, Qualys, Shopify and Under Armour.
Judging by the most shorted stocks traded on the Nasdaq between the September 14 and September 28 settlement dates, those sellers were looking for direction.
Geron, Ford, Conagra, and Bed, Bath & Beyond all posted new 52-week lows Thursday.
Geron shares were absolutely crushed on Thursday morning after it was announced that Janssen Biotech has terminated the 2014 collaboration and license agreement with the firm.
Chris Lange Judging by the most shorted stocks traded on the Nasdaq between the August 31 and September 14 settlement dates, those sellers were focused on Qualcomm.
Judging by the most shorted stocks traded on the Nasdaq between the August 15 and August 31 settlement dates, those sellers may have been looking for direction.
Judging by the most shorted stocks traded on the Nasdaq between the July 31 and August 15 settlement dates, those sellers were focused on one favorite -- Caesars Entertainment.
Judging by the most shorted stocks traded on the Nasdaq between the July 31 and August 15 settlement dates, those sellers were focused on one favorite -- Caesars Entertainment.
Judging by the most shorted stocks traded on the Nasdaq between the July 13 and July 31 settlement dates, those sellers were looking for direction, as moves in their favorites were mixed…
Judging by the most shorted stocks traded on the Nasdaq between the June 29 and July 13 settlement dates, those sellers were cautious, as their favorites saw shrinking or flat short interest.
Judging by the most shorted stocks traded on the Nasdaq between the June 15 and June 29 settlement dates, those sellers were focused on a few of favorites.
The top analyst upgrades, downgrades and other research calls from Thursday include Allergan, Cheniere Energy, Clean Energy, Facebook, Fiat Chrysler, Intel and NetApp.
Geron Corporation is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for blood cancers (hematologic malignancies).
The Wall Street consensus 12-month price target for GERN is $4.25.
